Evaluation of the combined effect of Mahatriphladi Ghrita Nasya, Tarpana, Pana and Rakta-mokshana in Adhimantha (POAG)

Patanjali Bhartiya Ayurvigyan evam Anusandhana Sansthana Haridwar1 个研究点分布在 1 个国家目标入组 30 人开始时间: 2022年5月23日最近更新: 2022年7月22日

试验速览

阶段: 1/2 期
状态: 招募中
发起方
入组人数: 30
试验地点: 1
主要终点: SUBJECTIVE PARAMETER

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study is a randomized, open-labeled, parallel-group, clinical trial, to the evaluation of the combined effect of Mahatriphladi ghrita Nasya, Tarpana, pana and Rakta-mokshana in Adhimantha (POAG). patients of Adhimantha (POAG) will be selected from the OPD/IPD of shalakya department of Patanjali ayurvedic hospital, Haridwar, Uttarakhand and shri krishna eye institute Haridwar. The study will be conducted on a total of 30 patients (15 patients in each group) based on inclusion and exclusion criteria depending on the detailed clinical history, physical examination, and other necessary investigation and irrespective of their gender, caste, or creed.

研究设计

研究类型: Interventional
分配方式: Computer generated randomization
盲法: Open Label

入排标准

年龄范围: 30.00 Year(s) 至 70.00 Year(s)（—）
性别: All

入选标准

•Age 30 To 70 years
•Patients of either sex.
•Patients of POAG having IOP < 21mmHg and IOP > 21 mmHg.
•Visual acuity more than 6/60 and clear media.
•Patients of POAG.

排除标准

•1.Age below 30 years and above 70 years.
•Visual acuity less than 6/60
•Secondary and developmental Glaucoma including exfoliative glaucoma, pigmentary glaucoma,trauma-induced, inflammatory glaucoma, family history of glaucoma
•Evidence of any anterior segment pathology like conjunctivitis, keratitis, or acute uveitis.
•History of opaque ocular media (as in cataracts, corneal opacities, vitreous opacities).
•Pregnant women 7.Any malignancy, uncontrolled diabetes, uncontrolled hypertension.
•Contraindicated for Nasya.
•10.Contraindicated for Tarpana.
•Contraindicated for Rakta-mokshana (jalaukavcharan).